EMBRYO-FETAL TOXICITY
See full prescribing information for complete boxed warning
- TRADE NAME: Daurismo (Pfizer)
- INDICATIONS: indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
- CLASS: Hedgehog (Hh) signaling pathway inhibitor
- HALF-LIFE: 17.4 hours
- FDA APPROVAL DATE: 11/21/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: can cause fetal harm, not recommended for use during pregnancy
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
